Showing results (301-310 of 396) with videos related to
Sort By:
Pageof 40
Neuropathology and Applied Neurobiology|July 28, 2023
A threshold for mitotic activity and post-surgical residual volume defines distinct prognostic groups for astrocytoma IDH-mutantSuzanne Tran, Alice Thomas, Ilyes Aliouat, et al.Acta Neuropathologica|November 16, 2011
Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meetingMichel Kalamarides, Maria T Acosta, Dusica Babovic-Vuksanovic, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2007
Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group studyMurielle E L Mauer, Martin J B Taphoorn, Andrew Bottomley, et al.Neuro-Oncology|October 10, 2024
Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection-Update 1Martin J van den Bent, Enrico Franceschi, Mehdi Touat, et al.Neuro-Oncology Advances|June 10, 2024
Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: A phase 2 multicenter study of the POLA NetworkInes Esparragosa Vazquez, Marc Sanson, Olivier L Chinot, et al.Cancer Biomarkers : Section a of Disease Markers|August 12, 2017
Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patientsVéronique Quillien, Audrey Lavenu, François Ducray, et al.European Journal of Human Genetics : EJHG|August 13, 2015
Search for new loci and low-frequency variants influencing glioma risk by exome-array analysisBen Kinnersley, Yoichiro Kamatani, Marianne Labussière, et al.Oncotarget|August 20, 2016
Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trialVéronique Quillien, Audrey Lavenu, François Ducray, et al.Annals of Neurology|May 1, 2007
Dynamic history of low-grade gliomas before and after temozolomide treatmentDamien Ricard, Gentian Kaloshi, Alexandra Amiel-Benouaich, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2010
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor GroupMartin J van den Bent, Hendrikus J Dubbink, Yannick Marie, et al.Pageof 40